-Tehelka The NDA government’s move to open more Jan Aushadhi stores ignores the multitude of issues currently plaguing them Amidst the jostling crowd at the Guru Teg Bahadur Hospital in Shahdara, Delhi, is 68-year-old Suresh Chandra, holding his medical files on one hand and prescription letter on the other. Chandra, who is a lung disease patient, moves towards the Jan Aushadhi store, situated in the hospital premises. Chandra hopes that the government-run medical...
More »SEARCH RESULT
Total Matching Records found : 19
Overdependence on China for drug ingredients worries NSA -Sushmi Dey
-The Times of India NEW DELHI: India runs the risk of a severe shortage of medicines because of its over dependence on China for sourcing raw material for drugs, national security adviser (NSA) Ajit Doval has warned, TOI has learnt. According to the NSA, India should take immediate concrete steps to create adequate infrastructure to become self-sufficient for manufacturing medicines which are essential in nature. "The national security adviser had highlighted concerns related...
More »Drug pricing policies bent to favour pharma industry, allege health experts -Jyotsna Singh
-Down to Earth Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports Indicating failure of the National Pharmaceutical Pricing Policy (NPPP), 2012 and the Drugs Price Control Order (DPCO), 2013, two recently-released reports have stated that medicines are still not accessible and affordable for the citizens of the country. The reports that were jointly released...
More »Ranbaxy drugs fine, say WHO and UK regulator -Rema Nagarajan
-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...
More »Indian pharma's generic challenge-DG Shah
-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...
More »
